Dr. Seema Kantak is a visionary Biopharma R&D Strategy and Operations Executive. She has a record of scientific and operational success in protein therapeutics, discovering and developing new molecules and applications, optimizing product-driven R&D operations, and delivering profitable revenue growth in biotechnology and pharmaceutical industries. Seema is an inspirational, trusted leader who articulates strategic vision, inspires confidence with internal and external business partners, and builds business environments and cultures that motivate and engage high-performing teams. Impeccable biology and pharmacology credentials and inventor on several patents. ♦ Developed strategic roadmap to advance discovery/development of antibodies, bispecifics and multivalents and proteins. Project team leader for Research and IND studies on Nektar's leading Immuno-Oncology asset NKTR-214 – $3B+ pipeline value. ♦ Built relationships with respected medical centers and Biopharma companies, advancing strategic agenda. Initiated Nektar's collaboration with MD Anderson on NKTR-214 Immuno-Oncology asset. ♦ Discovered/generated candidates for 5 preclinical proprietary pipelines. Worked on 80+ research molecules, advancing 10 molecules to Phase I clinical trials and 5 to Phase II-III trials, with $4B+ potential.